Evaluation of Oral Tetrahydrouridine- Decitabine As Non- Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease

Evaluation of Oral Tetrahydrouridine- Decitabine As Non- Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease

User Photo
ASHReport

3 years
291 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Yogenthiran Saunthararajah, MD of Cleveland Clinic gives an overview of his abstract, Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease, that was presented at the 58th ASH Annual Meeting in San Diego, CA.

Up Next Autoplay